Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

(±) -Ibipinabant

Catalog No: tcsc6430

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
362519-49-1

Formula:
$C_{23}H_{20}Cl_2N_4O_2S$

Pathway:
GPCR/G Protein

Target:
Cannabinoid Receptor

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 31 mg/mL (63.60 mM)

Alternative Names:
(±)-SLV319;(±)-BMS6462

Observed Molecular Weight:
487.4

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (**CB-1**) receptor antagonist with an **IC_{50}** of 22 nM.

IC50 & Target: IC50: 22 nM (CB-1)[1]; Ki: 7.8 nM (CB-1)[2]

In Vitro: Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [K_i (CB1)=7.8 nM] and selective [K_i (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with *in vitro* pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance[3].

In Vivo: (±)-Ibipinabant ((±)-SLV319) (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with (±)-Ibipinabant ((±)-SLV319) significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later[3].